Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects.

Next Previous
Trial Profile

A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imagabalin (Primary) ; Lithium
  • Indications Cluster headache; Depression; Generalised anxiety disorder; Mania; Migraine
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 26 Feb 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 26 Feb 2009 Actual initiation date (May 2009) added as reported by ClinicalTrials.gov.
  • 25 Feb 2009 Pfizer has decided to discontinue development of this drug for the treatment of generalised anxiety disorder, as reported in a media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top